Inspired by ASH data, Merck's Roger Perlmutter swoops in with a $2.75B ROR1 buyout aimed at beefing up the cancer pipeline
Roger Perlmutter has a few more moves to make before he exits the top job in Merck R&D.
The pharma giant is buying VelosBio …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
